BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang X, Li Y, Sun Y, Zhang M, Guo C, Mirza IA, Li Y. Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases. Dig Dis Sci 2018;63:302-11. [DOI: 10.1007/s10620-017-4866-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Scarpignato C, Hongo M, Wu JCY, Lottrup C, Lazarescu A, Stein E, Hunt RH. Pharmacologic treatment of GERD: Where we are now, and where are we going? Ann N Y Acad Sci 2020;1482:193-212. [PMID: 32935346 DOI: 10.1111/nyas.14473] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Liu C, Feng BC, Zhang Y, Li LX, Zuo XL, Li YQ. The efficacy of vonoprazan for management of post‐endoscopic submucosal dissection ulcers compared with proton pump inhibitors: A meta‐analysis. J Dig Dis 2019;20:503-11. [DOI: 10.1111/1751-2980.12813] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
3 Peng C, Hu Y, Ge ZM, Zou QM, Lyu NH. Diagnosis and treatment of Helicobacter pylori infections in children and elderly populations. Chronic Dis Transl Med 2019;5:243-51. [PMID: 32055783 DOI: 10.1016/j.cdtm.2019.12.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
4 Gunaratne AW, Hamblin H, Clancy A, Magat AJMC, Dawson MVM, Tu J, Borody TJ. Combinations of antibiotics and vonoprazan for the treatment of Helicobacter pylori infections-Exploratory study. Helicobacter 2021;:e12830. [PMID: 34247436 DOI: 10.1111/hel.12830] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Hirata Y, Yamada A, Niikura R, Shichijo S, Hayakawa Y, Koike K. Efficacy and safety of a new rifabutin‐based triple therapy with vonoprazan for refractory Helicobacter pylori infection: A prospective single‐arm study. Helicobacter 2020;25. [DOI: 10.1111/hel.12719] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
6 Scarpignato C, Hunt RH. The potential role of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease. Current Opinion in Gastroenterology 2019;35:344-55. [DOI: 10.1097/mog.0000000000000543] [Cited by in Crossref: 12] [Article Influence: 4.0] [Reference Citation Analysis]
7 Huh KY, Chung H, Kim YK, Lee S, Bhatia S, Takanami Y, Nakaya R, Yu KS. Evaluation of safety and pharmacokinetics of bismuth-containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication. Br J Clin Pharmacol 2021. [PMID: 34080718 DOI: 10.1111/bcp.14934] [Reference Citation Analysis]
8 Zhou Y, Ji X, Chen J, Fu Y, Huang J, Guo R, Zhou J, Cen J, Zhang Q, Chu A, Huang Y, Xu C, Wang F. Short-chain fatty acid butyrate: A novel shield against chronic gastric ulcer. Exp Ther Med 2021;21:329. [PMID: 33732302 DOI: 10.3892/etm.2021.9760] [Reference Citation Analysis]
9 Patel D, Bertz R, Ren S, Boulton DW, Någård M. A Systematic Review of Gastric Acid-Reducing Agent-Mediated Drug-Drug Interactions with Orally Administered Medications. Clin Pharmacokinet 2020;59:447-62. [PMID: 31788764 DOI: 10.1007/s40262-019-00844-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 16.0] [Reference Citation Analysis]
10 Hunt RH, Scarpignato C. Potent Acid Suppression with PPIs and P-CABs: What’s New? Curr Treat Options Gastro 2018;16:570-90. [DOI: 10.1007/s11938-018-0206-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
11 Savarino V, Antonioli L, Fornai M, Marabotto E, Demarzo MG, Zingone F, Ghisa M, Barberio B, Zentilin P, Ribolsi M, Savarino E. An update of pharmacology, efficacy, and safety of vonoprazan in acid-related disorders. Expert Rev Gastroenterol Hepatol 2021;:1-10. [PMID: 34550866 DOI: 10.1080/17474124.2021.1984878] [Reference Citation Analysis]
12 Cheng Y, Liu J, Tan X, Dai Y, Xie C, Li X, Lu Q, Kou F, Jiang H, Li J. Direct Comparison of the Efficacy and Safety of Vonoprazan Versus Proton-Pump Inhibitors for Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis. Dig Dis Sci 2021;66:19-28. [PMID: 32095968 DOI: 10.1007/s10620-020-06141-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
13 Kang H, Kim BJ, Choi G, Kim JG. Vonoprazan versus proton pump inhibitors for the management of gastroesophageal reflux disease: A protocol for a systematic review with meta-analysis. Medicine (Baltimore) 2018;97:e12574. [PMID: 30278564 DOI: 10.1097/MD.0000000000012574] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
14 Mousavi T, Nikfar S, Abdollahi M. The pharmacotherapeutic management of duodenal and gastric ulcers. Expert Opin Pharmacother 2021;:1-27. [PMID: 34435515 DOI: 10.1080/14656566.2021.1959914] [Reference Citation Analysis]
15 Ribaldone DG, Astegiano M. Comment #2 on "First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin". Gastroenterol Res Pract 2018;2018:5260358. [PMID: 30647734 DOI: 10.1155/2018/5260358] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Tsujita K, Deguchi H, Uda A, Sugano K. Upper gastrointestinal bleeding in Japanese patients with ischemic heart disease receiving vonoprazan or a proton pump inhibitor with multiple antithrombotic agents: A nationwide database study. Journal of Cardiology 2020;76:51-7. [DOI: 10.1016/j.jjcc.2020.02.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
17 Domingues G, Moraes-Filho JPP. GASTROESOPHAGEAL REFLUX DISEASE: A PRACTICAL APPROACH. Arq Gastroenterol 2021;58:525-33. [PMID: 34909861 DOI: 10.1590/S0004-2803.202100000-94] [Reference Citation Analysis]
18 Saito M, Koike T, Abe Y, Nakagawa K, Kanno T, Jin X, Hatta W, Uno K, Asano N, Imatani A, Fujishima F, Masamune A. The Development of Foveolar-type Gastric Adenocarcinoma during Maintenance Therapy of Vonoprazan for Reflux Esophagitis. Intern Med 2021;60:391-6. [PMID: 32863366 DOI: 10.2169/internalmedicine.5431-20] [Reference Citation Analysis]
19 Costa P, Almeida MO, Lemos M, Arruda C, Casoti R, Somensi LB, Boeing T, Mariott M, da Silva RCMVAF, Stein BP, Souza P, Dos Santos AC, Bastos JK, da Silva LM, Andrade SF. Artepillin C, drupanin, aromadendrin-4'-O-methyl-ether and kaempferide from Brazilian green propolis promote gastroprotective action by diversified mode of action. J Ethnopharmacol 2018;226:82-9. [PMID: 30107246 DOI: 10.1016/j.jep.2018.08.006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 4.8] [Reference Citation Analysis]
20 Miftahussurur M, Pratama Putra B, Yamaoka Y. The Potential Benefits of Vonoprazan as Helicobacter pylori Infection Therapy. Pharmaceuticals (Basel) 2020;13:E276. [PMID: 32998241 DOI: 10.3390/ph13100276] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Kang H, Kim BJ, Choi G, Kim JG. Vonoprazan versus proton pump inhibitors for the management of gastric endoscopic submucosal dissection-induced artificial ulcer: A systematic review with meta-analysis. Medicine (Baltimore) 2019;98:e15860. [PMID: 31192917 DOI: 10.1097/MD.0000000000015860] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
22 Livzan MA. [Underwater rocks of anti - helicobacter therapy]. Ter Arkh 2019;91:141-7. [PMID: 32598766 DOI: 10.26442/00403660.2019.08.000386] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 O'Morain NR, Dore MP, O'Connor AJP, Gisbert JP, O'Morain CA. Treatment of Helicobacter pylori infection in 2018. Helicobacter 2018;23 Suppl 1:e12519. [PMID: 30203585 DOI: 10.1111/hel.12519] [Cited by in Crossref: 30] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]